XORTX Therapeutics Inc.

TSXV:XRTX Stock Report

Market Cap: CA$6.3m

XORTX Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Allen Davidoff

Chief executive officer

US$322.0k

Total compensation

CEO salary percentage79.2%
CEO tenure7yrs
CEO ownership2.2%
Management average tenure3.1yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Here's Why We're Watching XORTX Therapeutics' (CVE:XRTX) Cash Burn Situation

Aug 23
Here's Why We're Watching XORTX Therapeutics' (CVE:XRTX) Cash Burn Situation

XORTX Therapeutics (CVE:XRTX) Is In A Strong Position To Grow Its Business

Apr 01
XORTX Therapeutics (CVE:XRTX) Is In A Strong Position To Grow Its Business

We're Interested To See How XORTX Therapeutics (CVE:XRTX) Uses Its Cash Hoard To Grow

Dec 16
We're Interested To See How XORTX Therapeutics (CVE:XRTX) Uses Its Cash Hoard To Grow

Companies Like XORTX Therapeutics (CSE:XRX) Can Afford To Invest In Growth

Sep 01
Companies Like XORTX Therapeutics (CSE:XRX) Can Afford To Invest In Growth

CEO Compensation Analysis

How has Allen Davidoff's remuneration changed compared to XORTX Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$737k

Jun 30 2024n/an/a

-US$1m

Mar 31 2024n/an/a

-US$3m

Dec 31 2023US$322kUS$255k

-US$2m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$7m

Mar 31 2023n/an/a

-US$7m

Dec 31 2022US$321kUS$273k

-US$8m

Sep 30 2022n/an/a

US$1m

Jun 30 2022n/an/a

-US$3m

Mar 31 2022n/an/a

-US$2m

Jan 01 2022n/an/a

-US$2m

Sep 30 2021n/an/a

-US$9m

Jun 30 2021n/an/a

-US$3m

Mar 31 2021n/an/a

-US$3m

Dec 31 2020US$204kUS$154k

-US$1m

Sep 30 2020n/an/a

-US$767k

Jun 30 2020n/an/a

-US$536k

Mar 31 2020n/an/a

-US$362k

Dec 31 2019US$161kUS$148k

-US$485k

Sep 30 2019n/an/a

-US$444k

Jun 30 2019n/an/a

-US$582k

Mar 31 2019n/an/a

-US$660k

Dec 31 2018US$194kUS$141k

-US$3m

Compensation vs Market: Allen's total compensation ($USD321.96K) is above average for companies of similar size in the Canadian market ($USD166.13K).

Compensation vs Earnings: Allen's compensation has increased whilst the company is unprofitable.

CEO

Allen Davidoff (64 yo)

7yrs

Tenure

US$321,959

Compensation

Dr. Allen Warren Davidoff, Ph.D. is Founder of XORTX Therapeutics Inc. (formerly known as XORTX Pharma Corp.) and has been its Chief Executive Officer and President since January 9, 2018. Dr. Davidoff serv...

Leadership Team

NamePositionTenureCompensationOwnership
Allen Davidoff
Founder7yrsUS$321.96k2.23%
CA$ 140.4k
Stephen Haworth
Chief Medical Officer3.5yrsUS$173.37k0%
CA$ 0
Stacy Evans
Chief Business Officer2.2yrsUS$211.33kno data
Michael Bumby
Chief Financial Officerless than a yearno datano data
Nick Rigopoulos
Director of Communicationsno datano datano data
David Sans
Director of Corporate Development4.4yrsno datano data
David MacDonald
Consultant of Clinical Operations2.7yrsno datano data
Charlotte May
Corporate Secretaryno datano datano data

3.1yrs

Average Tenure

60yo

Average Age

Experienced Management: XRTX's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Allen Davidoff
Founder7yrsUS$321.96k2.23%
CA$ 140.4k
Paul Van Damme
Independent Director7yrsUS$8.20k0.20%
CA$ 12.9k
Anthony Giovinazzo
Independent Chair of the Board2.6yrsUS$101.11k0.28%
CA$ 17.4k
Richard Johnson
Member of Clinical Advisory Boardno datano datano data
William Farley
Independent Director3.7yrsUS$7.87k0%
CA$ 0
Raymond Pratt
Independent Director3.1yrsUS$7.37k0%
CA$ 0
Henk E. D. ter Keurs
Member of Scientific Advisory Boardno datano datano data
Federico Maese
Member of Clinical Advisory Board6.3yrsno datano data
Patrick Treanor
Independent Director1.1yrsno data0%
CA$ 0
Petter Bjornstad
Member of Clinical Advisory Board6.3yrsno datano data
Anjay Rastogi
Member of the Clinical Advisory Board4.8yrsno datano data
Charles Edelstein
Member of the Advisory Board3.4yrsno datano data

4.3yrs

Average Tenure

68.5yo

Average Age

Experienced Board: XRTX's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 10:48
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

XORTX Therapeutics Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Chris ThompsoneResearch Corporation